Yeah, it's good stuff. I think the overlooked aspect is that a generic could have filed an ANDA with the summary judgement declaring there is significant use for non-infringement (the less than 12 week claim). This needs to be overturned as well.
The fact that generics had this and still have yet to get a ANDA approved is telling in their confidence that they will bring this to market. They know an injunction does not go in their favor, other than having AMRN post a bond (cost of capital) that betters their position in a settlement.
News 
Market Data 
Discover 
AI
